Federal contract award

75F40123C00195

NALOXONE USAGE, SAFETY, AND EFFICACY IN PREHOSPITAL ENVIRONMENT FOR CONVENTIONAL AND EMERGING SYNTHETIC OPIOIDS AND OTHER COMIXTURES TOPICAL.

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Health and Human Services
OfficeFDA OFFICE OF ACQ GRANT SVCS
NAICS541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSCB504 — Chemical/Biological Studies and Analysis
Parent award / vehicleNot reported
Set-asideNO SET ASIDE USED.
Pricing typeFIRM FIXED PRICE
Obligations$522.2K
Current contract value$522.2K
Potential contract value / ceiling$522.2K
Start dateSep 21, 2023
Current end dateSep 29, 2024
Potential end dateSep 29, 2024
Latest award activityJul 11, 2025
Source loadedAug 15, 2026

Funding and modification history

Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Jul 11, 2025P00002$-1.0KNO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO DECEMBER 31, 2024.

Buyer contacts from matching notices

Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.

ContactRolePublished contact methodsEvidenceSource date
Ian WeissContactIan.Weiss@fda.hhs.gov
(301) 796-5728
SourceMay 18, 2023
Ravi Chandan PalaniandyContactRaviChandan.Palaniandy@fda.hhs.gov
301-796-4378
SourceMay 18, 2023
Ian WeissContactIan.Weiss@fda.hhs.gov
(301) 796-5728
SourceJan 17, 2023
Ravi Chandan PalaniandyContactRaviChandan.Palaniandy@fda.hhs.gov
301-796-4378
SourceJan 17, 2023
Ian WeissContactIan.Weiss@fda.hhs.gov
(301) 796-5728
SourceJan 9, 2023
Ravi Chandan PalaniandyContactRaviChandan.Palaniandy@fda.hhs.gov
301-796-4378
SourceJan 9, 2023
Ian WeissContactIan.Weiss@fda.hhs.gov
(301) 796-5728
SourceJan 9, 2023
Ravi Chandan PalaniandyContactRaviChandan.Palaniandy@fda.hhs.gov
301-796-4378
SourceJan 9, 2023
Ian WeissContactIan.Weiss@fda.hhs.gov
(301) 796-5728
SourceJan 4, 2023
Ravi Chandan PalaniandyContactRaviChandan.Palaniandy@fda.hhs.gov
301-796-4378
SourceJan 4, 2023
Ian WeissContactIan.Weiss@fda.hhs.gov
(301) 796-5728
SourceJan 4, 2023
Ravi Chandan PalaniandyContactRaviChandan.Palaniandy@fda.hhs.gov
301-796-4378
SourceJan 4, 2023
Ian WeissContactIan.Weiss@fda.hhs.gov
(301) 796-5728
SourceJan 3, 2023
Ravi Chandan PalaniandyContactRaviChandan.Palaniandy@fda.hhs.gov
301-796-4378
SourceJan 3, 2023
Ian WeissContactIan.Weiss@fda.hhs.gov
(301) 796-5728
SourceNov 17, 2022
Ravi Chandan PalaniandyContactRaviChandan.Palaniandy@fda.hhs.gov
301-796-4378
SourceNov 17, 2022
Ian WeissContactIan.Weiss@fda.hhs.gov
(301) 796-5728
SourceNov 14, 2022
Ravi Chandan PalaniandyContactRaviChandan.Palaniandy@fda.hhs.gov
301-796-4378
SourceNov 14, 2022

Research next steps

  1. Check the stated set-aside against the solicitation and current certifications.
  2. Review the award scope and buyer evidence before making a bid/no-bid decision.